- 9 minutes 31 secondsAdvances in a Capsule: October 2026 | JACC: Advances
Audio Summary of three articles from the October 2026 issue of JACC: Advances.
29 October 2026, 11:20 am - 4 minutes 35 secondsXGBoost Model with CMR Features for Prognostic Assessment in Patients With ST‑Segment Elevation Myocardial Infarction | JACC: Asia
Commentary by Dr. Yoriyasu Suzuki.
20 October 2026, 6:00 pm - 4 minutes 16 secondsDesign and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease | JACC: Asia
Commentary by Dr. Junjie Yang.
20 October 2026, 5:35 pm - 3 minutes 7 secondsPrediction of Paroxysmal Atrial Fibrillation with Incorporating Genomic Information Into AI-Based ECG Analysis | JACC: Asia
Commentary by Dr. Qinkai Yu.
20 October 2026, 5:20 pm - 1 minute 50 secondsOctober 2026 Summary | JACC: CardioOncology
Editor-in-Chief Dr. Bonnie Ky introduces the October 2026 issue of JACC: CardioOncology, featuring Part 1 of a special focus on immunology and cardio-oncology. This issue brings together state-of-the-art reviews, primers, original research, and clinical cases examining the immune system's central role in cancer and cardiovascular disease. Topics include the mechanisms and clinical implications of cancer immunotherapies and the immune system's contributions to the cardiovascular effects of cytotoxic chemotherapy, with implications for scientific discovery and patient care.
20 October 2026, 3:40 pm - 2 minutes 36 secondsFibrotic Rewiring of CD8+ T-cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix | JACC: CardioOncology
Dr. Caitlin O'Meara discusses a JACC: CardioOncology study showing that doxorubicin reprograms CD8+ T cells into matrix-remodeling T cells (mxT-cells) that produce lysyl oxidase (LOX) and stiffen the cardiac extracellular matrix through HIF1α-P53-TGFβ signaling. She explains how this new immune mechanism of anthracycline cardiotoxicity could lead to therapies that prevent cardiac fibrosis, cardiomyopathy, and heart failure in patients treated with chemotherapy.
20 October 2026, 3:25 pm - 5 minutes 3 secondsHigh-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors | JACC: CardioOncology
Dr. David Austin discusses a JACC: CardioOncology study showing that high-sensitivity cardiac troponin T was elevated in 37.9% of patients starting immune checkpoint inhibitor (ICI) therapy, compared with only 1.8% for high-sensitivity troponin I, a discordance linked to older age, male sex, and kidney dysfunction. He explains what this means for troponin assay selection, baseline testing, and ICI myocarditis surveillance, helping cardiologists and oncologists avoid unnecessary cancer treatment interruptions and immunosuppression.
20 October 2026, 3:15 pm - 3 minutes 30 secondsInflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis | JACC: CardioOncology
Dr. Cristina Gil-Cruz discusses a JACC: CardioOncology study comparing early- and late-manifestation immune checkpoint inhibitor (ICI) myocarditis, where endomyocardial biopsies showed greater T-cell and macrophage infiltration in early cases despite similar left ventricular ejection fraction and fibrosis. She explains what these inflammatory cell profiles mean for cardio-oncology care, from immunosuppression and ICI rechallenge to balancing cardiac safety with effective cancer immunotherapy.
20 October 2026, 2:39 pm - 3 minutes 33 secondsImpact of Device Position and Aortic Valve Prolapse on Outcomes After Transcatheter VSD Closure | JACC: Asia
Commentary by Dr. Timothy Un.
7 October 2026, 6:01 pm - 4 minutes 26 secondsPrognostic Impact of Residual Thrombus After Aspiration Thrombectomy in ST-Elevation Myocardial Infarction | JACC: Asia
Commentary by Dr. Ziyad Ghazzal.
7 October 2026, 5:46 pm - 3 minutes 22 secondsSex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials | JACC: Asia
Commentary by Dr. Yihang Fan.
7 October 2026, 5:41 pm - More Episodes? Get the App